mRNA Booster May Be Less Effective if Previously Infected
Additional protection offered by the initial COVID booster shot may be reduced among people with a previous COVID-19 infection, according to a study published in Plos Medicine.
Additional protection offered by the initial COVID booster shot may be reduced among people with a previous COVID-19 infection, according to a study published in Plos Medicine.
US influenza hospital admissions have hit the highest rate in a decade as vaccinations slump, US officials say.
Updated Covid booster shots targeting omicron’s BA.5 subvariant should be here within in the next three weeks.
An FDA vaccine advisory committee recommended future COVID-19 vaccine boosters should include a SARS-CoV-2 omicron BA.4/5 component for boosters beginning in fall 2022.
Read MoreThe COVID vaccine is not associated with an increased risk of heart attack or stroke in patients with established cardiovascular disease, according to a study of 229,235 CVD patients.
Read MoreTo examine the infectious periods in vaccinated individuals infected with the SARS-CoV-2 Omicron and Delta variants, researchers collected daily PCR tests from a group of college students and staff.
Read MoreCOVID-19 vaccines reduced the potential global death toll during the pandemic by more than half in the year following their implementation, a mathematical modeling study published in The Lancet Infectious Diseases estimates.
Read MoreNew research provides additional evidence that COVID-19 vaccination during pregnancy helps protect babies younger than 6 months from being hospitalized due to COVID-19.
Read MoreThe FDA authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 for in children as young as 6 months old.
Read MoreThe FDA’s Vaccine and Related Biological Products Advisory Committee voted unanimously in favor of authorizing the Moderna and Pfizer/BioNTech COVID-19 vaccines for children as young as 6-months old.
Read MoreInactivated and mRNA COVID-19 vaccines appear to be safe for patients treated for hypothyroidism, according to a new study being presented at ENDO 2022, the Endocrine Society’s annual meeting.
Read MoreA phase III trial investigating the GSK RSV vaccine candidate for adults aged 60 years and above exceeded its primary endpoint with no unexpected safety concerns observed, the company announced.
Read MoreA 50 µg dose of Moderna’s bivalent booster candidate, mRNA-1273.214, demonstrated superior neutralizing antibody response against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine.
Read MoreAlthough the U.S. commitment to developing Novavax’s COVID vaccine ballooned to $1.8 billion, hardly any Novavax shots have found arms due to manufacturing issues.
Read MoreNo one has a crystal ball to see which SARS-CoV-2 variant will come next or how good future variants will be at evading vaccine immunity. But looking to other respiratory viral foes that have troubled humanity for a while can suggest what the future could look like.
Read More